



Is Elevated Gastric Tissue NOX2 Associated with Lymphoma of Mucosa-Associated Lymphoid Tissue?

Emilie Bessède, Christiane Copie-Bergman, Philippe Lehours, Michael Levy,
Karen Leroy, Maryse Baia, Audrey Riou, Francis Mégraud, Jean-Charles
Delchier, Nathalie Salles

► To cite this version:

Emilie Bessède, Christiane Copie-Bergman, Philippe Lehours, Michael Levy, Karen Leroy, et al.. Is Elevated Gastric Tissue NOX2 Associated with Lymphoma of Mucosa-Associated Lymphoid Tissue?. *Antioxidants and Redox Signaling*, 2012, 16 (11), pp.1205-11. 10.1089/ars.2011.4494 . inserm-00696815

HAL Id: inserm-00696815

<https://inserm.hal.science/inserm-00696815>

Submitted on 14 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table 1. Clinical and molecular features of the 39 patients with primary gastric MALT lymphoma and 43 patients with gastritis (Control group).

	MALT lymphoma	Control group
Number of patients	39	43
Age at diagnosis	57.5	56
median age (range)	24-80	23-92
Men/women	23/16	20/23
Follow-up since diagnosis		
Median (range)	3 yrs [0-20yrs]	0
H. pylori-positive/ H. pylori-negative	19/20	17 /26
Extent of the disease		—
Stage IE*/IIE°/IV** (n)	23/9/7	
Molecular status at diagnosis		
Detectable t(11;18), n	17	0
Sydney score at diagnosis		
Activity ≥ 2	4 (10%)	10 (23%)
Inflammation ≥ 2	13 (33%)	26 (60%)
Atrophy ≥ 2	5 (12,8%)	6 (14%)
Intestinal metaplasia ≥ 2	3 (7%)	2 (4%)

*disease limited to the stomach

° perigastric lymph nodes on endoscopic ultra sound

** medullar and/or pulmonary involvement

Table 2. Expression of NOX2 and NOX5 in different biopsies according to the Updated Sydney system.

GML=39	Sydney score			Control group =43		
Sydney score (N = number of biopsies)	NOX5 mean	NOX2 mean	(N = number of biopsies)	NOX5 mean	NOX2 mean	
activity = 0 (N=26)	0.00069	0.42697	activity = 0 (N=27)	0.00229	0.11760	
activity = 1 (N=9)	0.00040	0.14821	activity = 1 (N=6)	0.00269	0.12649	
activity = 2 (N=2)	0.00012	0.12849	activity = 2 (N=4)	0.00056	0.07035	
activity = 3 (N=2)	0.00045	0.19357	activity = 3 (N=6)	0.00027	0.03783	
inflammation = 0 (N=1)	0.00386	4.40762	inflammation = 0 (N=2)	0.00024	0.04669	
inflammation = 1 (N=25)	0.00055	0.25169	inflammation = 1 (N=15)	0.00315	0.11444	
inflammation = 2 (N=12)	0.00035	0.18026	inflammation = 2 (N=22)	0.00152	0.10853	
inflammation = 3 (N=1)	0.00016	0.08105	inflammation = 3 (N=4)	0.00020	0.06120	
atrophy = 0 (N=28)	0.00055	0.36885	atrophy = 0 (N=29)	0.00186	0.11647	
atrophy = 1 (N=6)	0.00085	0.28605	atrophy = 1 (N=8)	0.00328	0.11401	
atrophy = 2 (N=5)	0.00034	0.18000	atrophy = 2 (N=4)	0.00029	0.01942	
atrophy = 3 (N=0)	-	-	atrophy = 3 (N=2)	0.00020	0.03762	
intestinal metaplasia = 0 (N=34)	0.00061	0.36438	intestinal metaplasia = 0 (N=37)	0.00218	0.11400	
intestinal metaplasia = 1(N=2)	0.00041	0.05450	intestinal metaplasia = 1 (N=4)	0.00021	0.04506	
intestinal metaplasia = 2 (N=2)	0.00020	0.15561	intestinal metaplasia = 2 (N=2)	0.00019	0.02215	
intestinal metaplasia = 3 (N=1)	0.00009	0.13490	intestinal metaplasia = 3 (N=0)	-	-	

